Chronic Refractory Tinnitus (Investigational Adjunct)
Investigational adjunct for chronic refractory subjective tinnitus; cognitive behavioral therapy, sound therapy, and hearing aids for concurrent hearing loss remain evidence-based.
Краткая информация для пациента
- Есть ли FDA-допуск для этого показания?
- Not FDA-cleared for chronic refractory (non-pulsatile) tinnitus. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- Какие доказательства существуют?
- Tier C (investigational). No controlled trials. Evidence-based first-line management of chronic non-pulsatile tinnitus is hearing aid fitting (if hearing loss is present, which it usually is), sound therapy (broadband sound generators, tinnitus retraining therapy), and cognitive behavioral therapy specifically for tinnitus distress — CBT has the strongest evidence for reducing tinnitus impact, though it does not eliminate the tinnitus itself.
- Основные риски
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- No mechanistic plausibility for chronic non-pulsatile tinnitus, which is a central auditory phenomenon
- Time and resources spent on leeches may delay proven interventions (hearing aids, CBT, sound therapy)
- Кому не следует это рассматривать
- Patients who have not had audiologic evaluation and hearing aid fitting
- Patients who have not tried tinnitus-specific CBT or tinnitus retraining therapy
- Patients with pulsatile tinnitus (different workup — see pulsatile tinnitus entry)
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
- People with hemophilia or any other inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL)
- People with an active infection at the planned application site
- О чём спросить врача
- Have I had a complete audiologic evaluation and been fitted for hearing aids if appropriate?
- Have I tried tinnitus-focused CBT or tinnitus retraining therapy?
- Has my tinnitus been confirmed as non-pulsatile (no vascular workup needed)?
- What is the published evidence base for leeches in chronic tinnitus?
- How will success be measured — Tinnitus Handicap Inventory, sleep quality, both?
- What is the plan if I do not improve?
- Когда срочно обратиться за медицинской помощью
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Sudden unilateral hearing loss or vertigo (possible inner-ear or neurologic emergency)
- Tinnitus that becomes pulsatile (new vascular workup needed)
- Severe distress with suicidal ideation (tinnitus distress can be serious)
Что это НЕ означает
- It does not mean leech therapy is FDA-cleared for tinnitus — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace hearing aids, sound therapy, or CBT — the proven interventions.
- It does not eliminate tinnitus (no current therapy reliably does).
- It does not address the central auditory remapping that drives chronic tinnitus.
- It does not have controlled-trial evidence in this indication.
Перекрёстные ссылки безопасности
Clinical Profile
- Category
- ent
- ICD-10
- H93.11, H93.12, H93.13, H93.19
- Safety tier
- high
Evidence Summary
Chronic subjective tinnitus is a common, often disabling symptom whose mechanism is incompletely understood but involves central neural plasticity. AAO-HNS evidence-based management focuses on coping rather than cure: cognitive behavioral therapy (strongest RCT evidence for distress reduction), tinnitus retraining therapy and sound therapy, hearing aids for those with concurrent hearing loss, and addressing comorbid anxiety and depression. Pharmacotherapy is not indicated as primary therapy. Pulsatile (vascular) tinnitus is a distinct entity requiring vascular workup and is covered separately. Older case series exist for hirudotherapy in tinnitus (with the most-cited being preauricular or mastoid placement); no controlled trials. Facial-region placement is uniquely high-risk.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Pulsatile tinnitus (vascular workup required)
- Untreated hearing loss (audiology referral first)
- Preauricular, mastoid, or facial placement (facial nerve and arterial risk)
- Active middle-ear pathology
- Severe anxiety or depression where CBT or psychiatry referral is primary
Related Conditions
Chronic Rhinosinusitis
Off-label use with one RCT showing symptom and SNOT-22 score improvement at 4 weeks in non-polypoid chronic sinusitis.
Subjective Tinnitus
Investigational use for chronic subjective tinnitus; case-series evidence for THI score improvement. Mechanism speculative.
Ménière's Disease (Adjunctive)
Investigational adjunctive use for Ménière's disease; very limited evidence. Standard management (diet, betahistine, intratympanic therapy) remains primary.
Pulsatile Tinnitus (Vascular-Origin Subtype)
Investigational use for pulsatile vascular-origin tinnitus distinct from subjective tinnitus; case-report evidence only.